High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma
Launched by THERACLION · Aug 23, 2011
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of breast fibroadenoma based on:Clinical examination, Ultrasound image and mammogram for women older than 35 years, and histology
- • Fibroadenoma size superior at 1 cm at its largest dimension (measured by Ultrasound)
- Exclusion Criteria:
- • Patient pregnant or lactating
- • Microcalcifications within the lesion at the mammogram.
- • History of breast cancer or history of laser or radiation therapy to the target breast
- • Breast implant in the target breast.
- • Fibroadenoma not clearly visible on the ultrasound images (in B mode)
- • Patient participating in other trials using drugs or devices
About Theraclion
Theraclion is a pioneering medical technology company specializing in the development and commercialization of innovative non-invasive ultrasound-based treatments for various medical conditions. Focused on enhancing patient care, Theraclion's flagship technology employs focused ultrasound to precisely target and treat tumors, offering a revolutionary alternative to traditional surgical methods. With an emphasis on clinical research and collaboration, Theraclion aims to advance the field of thermal ultrasound therapy, providing safe, effective, and patient-friendly treatment options. The company's commitment to innovation and excellence positions it at the forefront of the evolving healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lille, , France
Neuilly Sur Seine, , France
Patients applied
Trial Officials
Loïc BOULANGER, MD
Principal Investigator
Hôpital Jeanne de Flandre, CHU de Lille - FRANCE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials